Edward Lewis Tobinick graduated Phi Beta Kappa and Magna Cum Laude with honors in biology from Brandeis University in Waltham, Massachusetts, received his M.D. from the University of California San Diego School of Medicine in La Jolla, California, and completed post-graduate residencies at UCLA. He is the founder of the Institute of Neurological Recovery in Los Angeles, California and the INR PLLC in Boca Raton, Florida. Dr. Tobinick has been an invited ad hoc expert reviewer for the journals Brain Research, CNS Drugs, Current Alzheimer Research, Drug Discovery Today, Experimental Neurology, Future Neurology, Journal of Neurochemistry, Journal of Neuroimmunology, Neuroscience, and Pharmaceutical Medicine and a member of the Editorial Board of the Journal of Neuroinflammation. During Dr. Tobinick’s medical school training in neurology he developed a strong interest in the field that has lasted throughout his subsequent medical career.
Dr. Tobinick has presented his scientific findings regarding the effects of etanercept for neurological disorders at multiple U.S. and international medical and scientific conferences, including at the Days of Molecular Medicine Conference at the Karolinska Institute in Stockholm, Sweden in 2006; the 7th Annual Alzheimer’s Drug Discovery Conference in New York in 2006; the 2008 Drug Repositioning Summit in Boston; the International Conference on Alzheimer’s Disease in Chicago; the 7th Annual Alzheimer’s Drug Discovery Conference in New York; the 2008 Best Practices in the Continuum of Care: Advances in Alzheimer’s Disease Management conference at the University of Arkansas Medical Sciences in Little Rock, Arkansas; and, in 2009, the 3rd International Restauracion Neurologica Conference in Havana, Cuba, the World Pharmaceutical Congress in Philadelphia and the 5th Modern Drug Discovery Conference in San Diego. Dr. Tobinick has performed collaborative research with scientists from Stanford University School of Medicine and additional academic centers. Download a copy of Dr Tobinick’s Curriculum Vitae PDF Here.
Ed’s childhood was spent in New York City; he and his family moved to suburban New Jersey when he was 10. As a child he showed a keen interest in the natural world and science. He and his fellow 4-H members were featured on the cover of National 4-H News in 1963 (volumes 41-42, pp. 91 and 104) in an article discussing their interests in entomology and herpetology. His first mention in the scientific literature was in 1965, when he was 14 years old, in the Journal of the New York Entomological Society (Cutler, B., The Jumping Spiders of New York City (Araneae: Salticidae). Journal of the New York Entomological Society, 1965. 73(3): p. 138-143).
Selected Scientific Publications
- Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence. Ignatowski TA, Spengler RN, Dhandapani KM, Folkersma H, Butterworth RF, Tobinick E. CNS Drugs 2014, doi: 10.1007/s40263-014-0174-2.
- Immediate neurological recovery following perispinal etanercept years after brain injury. Tobinick E, Rodriguez-Romanacce H, Levine A, Ignatowski TA, Spengler RN. Clin Drug Investig. 2014 May;34(5):361-6.
- Selective TNF Inhibition for Chronic Stroke and Traumatic Brain Injury – An Observational Study Involving 629 Consecutive Patients Treated with Perispinal Etanercept. Edward Tobinick MD, Nancy M. Kim MD, et.al. CNS Drugs. 2012 Dec;26(12):1051-70.
- Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases. Edward Tobinick MD. CNS Drugs. 2011 Feb 1; 25(2):145-155.
- Perispinal etanercept: a new therapeutic paradigm in neurology. Edward Tobinick MD. Expert Review of Neurotherapeutics. 2010 Jun;10(6):985-1002.
- Tumour necrosis factor modulation for treatment of Alzheimer’s disease: rationale and current evidence. Edward Tobinick MD. CNS Drugs. 2009 Sep 1;23(9):713-25.
- The value of drug repositioning in the current pharmaceutical market. Edward Tobinick MD. Drug News Perspect. 2009 Mar;22(2):119-25. Review.
- Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging. Edward Tobinick MD, K Chen PhD, X Chen PhD. BMC Res Notes. 2009 Feb 27;2:28.
- Perispinal etanercept for neuroinflammatory disorders. Edward Tobinick MD. Drug Discovery Today. 2009 Feb;14(3-4):168-77.
- Perispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism. Edward Tobinick MD. Medscape J Med. 2008 Jun 10;10(6):135.
- Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer’s disease. Edward Tobinick MD, H. Gross MD. BMC Neurology. 2008 Jul 21;8:27.
- Re: Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Edward Tobinick MD. Neurology. 2008 Apr 1;70(14):1222-3.
- Perispinal etanercept for treatment of Alzheimer’s disease. Edward Tobinick MD. Current Alzheimer Research. 2007 Dec;4(5):550-2.
- A critique of intradiscal administration for treatment of radiculopathy. Edward Tobinick MD. Anesthesiology. 2008 Feb;108(2):334.
- Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration. Edward Tobinick MD, Hyman Gross MD. Journal of Neuroinflammation. 2008 Jan 9;5:2.
- Spinal delivery of p38: TNF-alpha inhibitors. E Tobinick MD. PLoS Med. 2006 Nov;3(11):e511.
- TNF-alpha modulation for treatment of Alzheimer’s disease: a 6-month pilot study. Edward Tobinick MD, Hyman Gross MD, Alan Weinberger MD, Hart Cohen MD. MedGenMed. 2006 Apr 26;8(2):25.
- The cerebrospinal venous system: anatomy, physiology, and clinical implications. Edward Tobinick MD. MedGenMed. 2006 Feb 22;8(1):53.
- Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients. Edward Tobinick MD, Susan Davoodifar MD. Curr Med Res Opin. 2004 Jul;20(7):1075-85.
- Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports. Edward L. Tobinick MD. Clinical Therapeutics. 2003 Aug;25(8):2279-88.